Aldeyra Therapeutics
ALDX
95 hedge funds and large institutions have $147M invested in Aldeyra Therapeutics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 24 increasing their positions, 28 reducing their positions, and 36 closing their positions.
345% more call options, than puts
Call options by funds: $1.96M | Put options by funds: $440K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3.12% less ownership
Funds ownership: 66.5% → 63.38% (-3.1%)
14% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 28
14% less funds holding
Funds holding: 111 → 95 (-16)
14% less capital invested
Capital invested by funds: $172M → $147M (-$24.9M)
39% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$3.34M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$2.56M |
| 3 |
Millennium Management
New York
|
+$2.52M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.31M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.72M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$6.43M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.42M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.81M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.47M |
ALDX Hedge Fund Activity: Q2 2022 in Review
95 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2022, worth a combined $147M — down 14% from $172M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ALDX and 22 opened new positions — a net loss of 14 holders — while 28 trimmed existing stakes and 24 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $3.34M. The largest seller was BlackRock, cutting an estimated $7.72M.
- 95 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2022, down from 111 in Q1 2022.
- Funds reported $147M of Aldeyra Therapeutics stock for Q2 2022, down 14% quarter-over-quarter.
- 22 funds opened new Aldeyra Therapeutics positions in Q2 2022 and 36 closed out, a net change of -14 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $3.34M added.
- The largest Aldeyra Therapeutics seller in Q2 2022 was BlackRock, an estimated $7.72M sold.
Based on aggregated 13F filings for Q2 2022.